The U.S. Food and Drug Administration approved asundexian (Sunharbo) on November 9, 2026, making it the first factor XIa inhibitor approved in the United States. In the pivotal trial, adding it to antiplatelet therapy after a non-cardioembolic stroke cut ischemic strokes by 26%.
For students and residents, this is a new drug class arriving on stroke wards, in pharmacology teaching and, once it ships, on discharge medication lists. It also comes with a sharp boundary: the same 50 mg dose lost to apixaban in atrial fibrillation, so knowing exactly who the label covers matters as much as the headline number.
A once-daily pill added to antiplatelets, for a defined group
According to the FDA, Sunharbo is approved for use with antiplatelet therapy to lower stroke risk in adults after a recent mild-to-moderate non-cardioembolic ischemic stroke or a high-risk transient ischemic attack (TIA). The agency stated plainly that it is not approved for stroke prevention in patients with atrial fibrillation.
The dose is 50 mg by mouth once daily, Bayer said in its approval announcement. The FDA granted the application Fast Track and Priority Review. Hylton V. Joffe, MD, director of the FDA's Office of Cardiology, Hematology, Endocrinology, and Nephrology, called the approval "a meaningful advance for patients and health care providers."
Bayer says China's regulator approved asundexian recently and that applications are under review elsewhere; TCTMD reported that Europe and Japan are among them.
The trial: 12,327 patients and 2.2 points fewer ischemic strokes
The approval rests on OCEANIC-STROKE, a phase 3, double-blind trial published in The New England Journal of Medicine in April 2026. Patients were randomized within 72 hours of a non-cardioembolic ischemic stroke or high-risk TIA to asundexian 50 mg or placebo, on top of planned single or dual antiplatelet therapy.
The trial did not enroll every stroke patient. Each participant had at least one of the following: a nonlacunar infarct on imaging, a history of atherosclerosis, or atherosclerotic plaque on cerebrovascular imaging.
- Ischemic stroke: 6.2% with asundexian vs. 8.4% with placebo (hazard ratio 0.74; 95% CI, 0.65 to 0.84).
- Major bleeding: 1.9% vs. 1.7% (hazard ratio 1.10; 95% CI, 0.85 to 1.44), which the authors described as similar.
- Serious adverse events: 19.2% vs. 19.5%.
The FDA puts the median treatment time at 14.2 months. The absolute gap of 2.2 percentage points works out to roughly one ischemic stroke avoided for every 45 patients treated during the trial, by MedRise's arithmetic from the published rates. Bayer funded the study.
The catch: older patients, the first 90 days and atrial fibrillation
Overall major bleeding matched placebo, but the FDA said it was higher with asundexian in patients over 75 and during the first 90 days of treatment. Healio reported those rates as 2.6 vs. 1.7 and 4.5 vs. 3.1 events per 100 patient-years, respectively. Gastrointestinal bleeding was also more common, and diarrhea was the most frequent side effect.
The bigger warning sign came earlier. In OCEANIC-AF, which tested the same 50 mg dose against apixaban in 14,810 patients with atrial fibrillation, the trial was stopped early. Stroke or systemic embolism occurred in 1.3% of asundexian patients vs. 0.4% on apixaban (hazard ratio 3.79), even though major bleeding was lower (0.2% vs. 0.7%).
Cost is another open question. TCTMD reported a list price of $748.50 for a 30-day supply, which Bayer says does not reflect what most patients pay.
What to know before you see it on rounds
- The class: asundexian inhibits activated factor XI. The NEJM authors note that people with low factor XI levels have a lower risk of ischemic stroke, the idea behind the drug.
- The indication: non-cardioembolic stroke or high-risk TIA, alongside antiplatelets. It is not an atrial fibrillation drug.
- Label details worth memorizing: the FDA says it is not recommended with combined P-gp and strong CYP3A4 inducers such as carbamazepine, or in moderate or severe hepatic impairment. It should be held at least 24 hours before elective surgery or invasive procedures and for at least 24 hours after thrombolysis.
- Review the basics: our anticoagulants vs. antiplatelets vs. thrombolytics guide covers the drugs asundexian will be compared with. More resources for trainees are on our students and residents pages.
What to watch next: decisions in Europe and Japan, and whether stroke guidelines adopt the drug. Ashkan Shoamanesh, MD, a co-principal investigator of the trial, named guideline incorporation, physician education and equitable access as the next steps, according to TCTMD.
Factor XI drugs were pitched as clot protection with less bleeding. Asundexian now has a U.S. label backing part of that pitch, and a stopped atrial fibrillation trial marking its limits.
Sources: FDA press announcement, Nov. 9, 2026; Bayer approval announcement; Sharma M, et al. Asundexian for Secondary Stroke Prevention. N Engl J Med 2026;394:1467-1479 (PubMed abstract); Piccini JP, et al. Asundexian versus Apixaban in Patients with Atrial Fibrillation. N Engl J Med 2024; TCTMD, Nov. 10, 2026; Healio, Nov. 10, 2026.
MedRise Medical News summarizes public announcements and research for education only. It is not medical, legal or immigration advice.


